PFIZER - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | PFIZER | Market Cap | 21,362 Cr. | Current Price | 4,677 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 28.2 | Book Value | 919 ₹ | Dividend Yield | 0.75 % | ROCE | 24.2 % |
| ROE | 18.0 % | Face Value | 10.0 ₹ | DMA 50 | 4,787 ₹ | DMA 200 | 4,906 ₹ |
| Chg in FII Hold | 0.10 % | Chg in DII Hold | -0.16 % | PAT Qtr | 193 Cr. | PAT Prev Qtr | 182 Cr. |
| RSI | 45.2 | MACD | -22.4 | Volume | 21,543 | Avg Vol 1Wk | 31,379 |
| Low price | 4,460 ₹ | High price | 5,993 ₹ | PEG Ratio | 3.49 | Debt to equity | 0.02 |
| 52w Index | 14.2 % | Qtr Profit Var | -2.64 % | EPS | 158 ₹ | Industry PE | 30.5 |
📊 Financial Overview: Pfizer India has a market cap of ₹21,362 Cr with a current price of ₹4,677. The 52-week range is ₹5,993–4,460. Profitability is strong with ROE at 18.0% and ROCE at 24.2%. Debt-to-equity ratio of 0.02 indicates negligible leverage. PAT stood at ₹193 Cr compared to ₹182 Cr in the previous quarter, showing stable earnings. EPS is ₹158, reflecting solid earnings capacity.
💰 Valuation Indicators: Stock P/E is 28.2, slightly below the industry average of 30.5, suggesting fair valuation. Book value is ₹919, giving a P/B ratio of ~5.1. PEG ratio of 3.49 indicates valuation is stretched relative to growth. Dividend yield of 0.75% provides modest shareholder returns. Intrinsic value appears close to current price, offering limited margin of safety.
💊 Business Model & Competitive Advantage: Pfizer India operates in pharmaceuticals, focusing on branded generics and specialty medicines. Its competitive advantage lies in global brand strength, R&D capabilities, and diversified product portfolio. Strong margins and low debt highlight overall financial health, though growth moderation is a concern.
📈 Entry Zone & Long-Term Guidance: The stock looks fairly valued at current levels. A better entry zone would be ₹4,500–4,650, closer to support levels. Long-term holding looks favorable given strong fundamentals, brand leadership, and consistent profitability, though investors should monitor growth and valuation metrics.
Positive
- 📈 [Strong Returns](ca://s?q=Pfizer_India_ROE_ROCE): ROE at 18.0% and ROCE at 24.2% are healthy.
- 🏦 [Low Debt](ca://s?q=Pfizer_India_debt_to_equity): Debt-to-equity ratio of 0.02 shows strong balance sheet.
- 💊 [Global Brand](ca://s?q=Pfizer_India_business_model): Strong presence in pharmaceuticals with diversified portfolio.
Limitation
- ⚖️ [High P/B Ratio](ca://s?q=Pfizer_India_PB_ratio): P/B of ~5.1 indicates valuation premium.
- 📉 [Profit Variation](ca://s?q=Pfizer_India_quarterly_profit): Quarterly profit variation at -2.64% shows slight instability.
- 📊 [PEG Ratio](ca://s?q=Pfizer_India_PEG_ratio): PEG of 3.49 suggests valuation stretched relative to growth.
Company Negative News
- 📉 [DII Exit](ca://s?q=Pfizer_India_DII_holdings): DII holdings decreased by -0.16%.
Company Positive News
- 📈 [FII Support](ca://s?q=Pfizer_India_FII_holdings): FII holdings increased by +0.10%.
- 📊 [Stable PAT](ca://s?q=Pfizer_India_PAT_growth): PAT rose slightly from ₹182 Cr to ₹193 Cr QoQ.
Industry
- 💊 [Pharma Sector](ca://s?q=India_pharma_industry): Industry PE at 30.5, showing moderate valuation compared to Pfizer India.
- 📊 [Healthcare Demand](ca://s?q=India_healthcare_growth): Rising demand for branded generics and specialty medicines supports sector expansion.
Conclusion
⚖️ Pfizer India’s fundamentals are strong with healthy profitability, low debt, and global brand advantage. While valuation is slightly stretched due to high P/B and PEG ratios, overall financial health and consistent earnings make it a solid candidate for long-term holding. Entry is advisable near ₹4,500–4,650 for better risk-reward balance.